Review
Neurosciences
Jamie J. Manning, Hayley M. Green, Michelle Glass, David B. Finlay
Summary: The CB1 receptor is a promising drug target for a wide range of diseases, but existing ligands have limited therapeutic potential. Recent drug development efforts have focused on altering CB1 signaling by modulating endocannabinoid signaling or selectively targeting specific cellular pathways.
Article
Pharmacology & Pharmacy
Senthil Jayarajan, Joseph J. Meissler, Martin W. Adler, Toby K. Eisenstein
Summary: The selective CB2 agonist O-1966 can block the proliferative response of mouse spleen cells and induce regulatory T cells in vitro. In vivo studies showed that O-1966 prolongs skin graft survival time and reduces spleen cell proliferation in response to allogeneic cells.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Neurosciences
Irene B. Maroto, Estefania Moreno, Carlos Costas-Insua, Javier Merino-Gracia, Rebeca Diez-Alarcia, Alicia Alvaro-Blazquez, Angeles Canales, Enric I. Canela, Vicent Casado, Leyre Uriguen, Ignacio Rodriguez-Crespo, Manuel Guzman
Summary: Cannabinoids have pleiotropic effects on the brain by interacting with the CB1 receptor. This study reveals that the interaction between CB1 receptor and GAP43 modulates CB1 receptor signaling in a highly selective manner, specifically impairing the ROCK signaling pathway and controlling neurite outgrowth.
Article
Multidisciplinary Sciences
Kathleen Shah, Muralidhara Rao Maradana, M. Joaquina Delas, Amina Metidji, Frederike Graelmann, Miriam Llorian, Probir Chakravarty, Ying Li, Mauro Tolaini, Michael Shapiro, Gavin Kelly, Chris Cheshire, Deendyal Bhurta, Sandip B. Bharate, Brigitta Stockinger
Summary: The aryl hydrocarbon receptor (AHR) plays a crucial role in regulating physiological processes in the intestine, influencing tissue regeneration and the acquisition of mature epithelial cell identity after injury.
NATURE COMMUNICATIONS
(2022)
Article
Chemistry, Medicinal
Michael Moir, Samuel Lane, Andrew P. Montgomery, David Hibbs, Mark Connor, Michael Kassiou
Summary: The development of selective CB2 receptor agonists is a promising therapeutic approach for inflammatory diseases. Through structure-activity relationship studies, a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine agonist has been discovered, with key structural features of the linkage group being important for its activity.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Biology
Stephanie E. Crilly, Wooree Ko, Zara Y. Weinberg, Manojkumar A. Puthenveedu
Summary: The study reveals that the same ligand can activate different active states of G protein-coupled receptors (GPCRs) in distinct cellular environments, allowing for coupling to different effectors. By investigating Golgi and surface pools, researchers can understand the receptor's different responses to drugs in different subcellular locations.
Article
Pharmacology & Pharmacy
Yaliang Tang, Barbara Wolk, Stevie C. Britch, Rebecca M. Craft, Debra A. Kendall
Summary: The study indicates that ABK5 has anti-inflammatory and analgesic effects, reducing inflammation and alleviating pain sensation. ABK5 may be a promising lead compound for the development of potential anti-inflammatory and analgesic agents.
JOURNAL OF PHARMACOLOGICAL SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Susanne Zellner, Martina Schifferer, Christian Behrends
Summary: The study investigates the formation of protein aggregates in fed conditions due to autophagy deficiency and the contribution of selective autophagy pathways to cellular proteostasis. Different receptors and substrates of aggrephagy are identified, with a systematic mapping of the autophagic degradome targeted by UBD-containing receptors under basal and proteostasis-challenging conditions.
Article
Dermatology
Victoria P. Werth, Emily Hejazi, Sandra M. Pena, Jessica Haber, Majid Zeidi, Nithin Reddy, Joyce Okawa, Rui Feng, Muhammad M. Bashir, Kirubel Gebre, Arvin S. Jadoo, Josef Symon S. Concha, Nancy Dgetluck, Scott Constantine, Barbara White
Summary: This study evaluated the safety and efficacy of lenabasum in patients with refractory cutaneous dermatomyositis. The results showed that lenabasum treatment was well tolerated and associated with greater improvement in Cutaneous Dermatomyositis Disease Area and Severity Index activity and multiple efficacy outcomes.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
George Amato, Vineetha Vasukuttan, Danni Harris, Lucas Laudermilk, Jennifer Lucitti, Scott Runyon, Rangan Maitra
Summary: Partial agonists targeting peripheral cannabinoid receptors have potential therapeutic applications in various medical conditions. In this study, a novel compound that is a partial agonist of the human CB1 receptor with reduced brain exposure was identified.
Review
Chemistry, Medicinal
Emil Marcher Rorsted, Anders A. Jensen, Jesper L. Kristensen
Summary: 25CN-NBOH, a potent and selective serotonin 2A receptor agonist, has been widely used in various studies due to its favorable physiochemical properties and superior selectivity. It has become an important pharmacological tool for exploring 5-HT2AR signaling in different animal models.
Article
Biochemistry & Molecular Biology
Antonella Capozzi, Daniela Caissutti, Vincenzo Mattei, Francesca Gado, Stefano Martellucci, Agostina Longo, Serena Recalchi, Valeria Manganelli, Gloria Riitano, Tina Garofalo, Maurizio Sorice, Clementina Manera, Roberta Misasi
Summary: This study evaluated the biological activity of a novel CBR2 agonist, JT11, and found that it has potential anti-inflammatory effects. Results showed that JT11 regulates cell viability and proliferation through a CBR2-dependent mechanism and reduces inflammation. These findings suggest that therapeutic strategies targeting CBR2 signaling may hold promise for the treatment of chronic inflammatory diseases.
Article
Biochemical Research Methods
Marie H. Deventer, Katleen Van Uytfanghe, Inge M. J. Vinckier, Fabiano Reniero, Claude Guillou, Christophe P. Stove
Summary: After the ban of synthetic cannabinoid receptor agonists (SCRAs) in China, new SCRAs carrying new core and linker structures are being introduced to avoid the recent generic legislation. This study evaluated the activity and selectivity of the previously unknown substance ADB-FUBIATA, which has been found in seized materials in multiple countries. The bioassays confirmed the potency and selectivity of ADB-FUBIATA, which differs from the previously known ADB-FUBICA.
DRUG TESTING AND ANALYSIS
(2022)
Article
Pharmacology & Pharmacy
Nathaniel A. K. Glenn, David B. Finlay, Emma R. Carruthers, Kathleen G. Mountjoy, Christopher S. Walker, Natasha L. Grimsey
Summary: The interactions between RAMPs and MRAPs with GPCRs play a significant role in modulating the expression and signaling of these receptors, particularly in cannabinoid receptors CB1, CB2, GPR18, and GPR55. The binding of CB1, CB2, and GPR55 with MRAPs influences their surface expression, possibly through glycosylation and hetero-oligomerization mechanisms, which potentially leads to physiological and disease-related consequences.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Chemistry, Medicinal
Gerasimos Rassias, Sofia Leonardi, Dionisia Rigopoulou, Eleanna Vachlioti, Konstantinos Afratis, Zoi Piperigkou, Christos Koutsakis, Nikos K. Karamanos, Haralambos Gavras, Dionissios Papaioannou
Summary: This study identified a novel B2 receptor agonist with significant antiproliferative activity in breast cancer cells, which may be achieved through multiple mechanisms, providing new insights for the development of anticancer drugs.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)